CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to ...

The prospectus describes RBD4059, one of Ribo Life's core candidate products, as the world's first and most advanced siRNA ...

AbbVie and ADARx Pharmaceuticals have announced a multi-billion dollar partnership to develop small interfering RNA (siRNA) ...

Apellis Pharmaceuticals focuses on creating medicines targeting eye diseases and rare neurological diseases. Read why I rate ...

Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, ...

In the Phase 2 study of patients with chronic kidney disease, the highest dose of the drug lowered by 86% the levels of ...

The Vallabh/Minikel lab at the Broad Institute has selected Argonaut Manufacturing Services, Inc., "Argonaut," as the drug ...

In 2021, GSK paid Arrowhead Pharmaceuticals $120 million up front for rights to the siRNA drug. Under GSK, GSK4532990 has reached mid-stage clinical development in both MASH and alcohol-related li ...

AbbVie and ADARx Pharmaceuticals have signed a collaboration and license option agreement to develop small interfering RNA ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...